Welcome to I-TECH HIV/AIDS Clinical Seminar Series November 19, 2009 Tuberculosis in Persons with HIV/AIDS: Opportunities for Prevention Charles Nolan,

Slides:



Advertisements
Similar presentations
TB 101 “Basic Facts on Tuberculosis”
Advertisements

Pulmonary Tuberculosis.
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
TB/HIV Research Priorities: TB Preventive Therapy.
TB Disease and Latent TB Infection
June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.
TUBERCULOSIS. What is Tuberculosis? Tuberculosis (TB) is an infectious disease caused by the bacterium: “Mycobacterium tuberculosis”
Tuberculosis in Children: Prevention Module 10C - March 2010.
World Health Organization TB Case Definitions
TB Presentation for Healthcare Students
Infection Control Overview: TB Session 1: Infection Control Basics.
Anders Chen, MD Internal Medicine R3 4/5/2011.  TB infection control (TB IC): Background  WHO Policy recommendations  Literature review  Practical.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
U. S. Senate Briefing World TB Day Celine Gounder, MD, ScM Center for TB Research, Johns Hopkins University Director for Delivery, CREATE On behalf of.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
West Virginia’s Tuberculosis Control Program Hx and Epi MissionTransmissionRequirements Channels of Communication.
Unit 4: Infection Control and Prevention of Tuberculosis
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.
This is a global infectious disease.
Unit 5: IPT Isoniazid TB Preventive Therapy
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
“Don’t tell me TB is under control!” Understanding TB
TUBERCULOSIS * Prevention * Treatment, and * Challenges.
Pediatric HIV/AIDS: Orphans & Vulnerable Children.
Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues Peter Godfrey-Faussett UNAIDS (with thanks.
Johns Hopkins Center for Tuberculosis Research
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
Welcome to I-TECH Nurse Clinical Seminar Series 19 August WHO Recommendations for TB Screening and IPT among People Living with HIV Stacie C.
Progress of the Singapore TB Elimination Programme (STEP)
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
TUBERCULOSIS Education Class. TB Information TB (Tuberculosis) is a chronic, communicable disease caused by the TB bacterium: “Mycobacterium tuberculosis”
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
A Self Study Powerpoint
Provider initiated testing in Kenya Ruth Nduati Associate Prof Paediatrics University of Nairobi.
Colleen Daniels Stop TB Department World Health Organisation TB, HIV and Drug Use The overview.
Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.
Unit 5 Isoniazid Prevention Therapy: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Prophylaxis of Opportunistic Infections
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
1 Communicating to Other Health Professionals About Your Patient: Doing Case Presentations HAIVN Harvard Medical School AIDS Initiative in Vietnam.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Tuberculosis in Children and Young Adults
The Strategic Health Authority for London London and TB 4 October 2007 Lynn Altass NHSL Public Health – TB North Central London TB Network Manager.
Using implementation science to improve child household contact screening for tuberculosis in Eldoret, Kenya: Overview and lessons learned Daria Szkwarko,
TB PREVENTION by Assoc. Prof. Dr. Nik Sherina Haidi Hanafi 1.
EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS. LEARNIN G OBJECTIVES State the diagnostic criteria of pulmonary tuberculosis Describe trend & state reasons for.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
Tuberculosis in children
Transmission and Pathogenesis
HEALTH PROMOTION.
Latent Infection In the nonimmune (susceptible) host, the bacilli initially multiply unopposed by normal host defense mechanisms. The organisms are then.
Tuberculosis prevention
William Burman Denver Public Health Tuberculosis Trials Consortium
Epidemiology of pulmonary tuberculosis
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
World Health Organization
بسم الله الرحمن الرحيم.
Mark Lobato, MD Division of TB Elimination
Tuberculosis Global Epidemiology
C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic
Anthony D Harries Ministry of Health, Malawi
Surveillance for TB in HIV Care and Treatment Settings (CTS)
5th edition NTP MANUAL OF PROCEDURES Case Finding
Presentation transcript:

Welcome to I-TECH HIV/AIDS Clinical Seminar Series November 19, 2009 Tuberculosis in Persons with HIV/AIDS: Opportunities for Prevention Charles Nolan, M.D.

Case for discussion A 22 yr old woman, recently diagnosed with HIV infection at the time of delivery of her second child, was referred for clinical and laboratory staging The evaluation revealed clinical stage 2 HIV infection (weight loss of perhaps a few kg over the past two months), and her CD4 cell count was 240 cells/mm3 The patient said that she has experienced a dry cough for around 3 weeks. She denied having fever.

Case for discussion (continued) How would you proceed to evaluate and manage this patient?

Considerations for this patient Further clinical evaluation because of symptoms – yes/no Antiretroviral therapy – yes/no Cotrimoxazole preventive therapy – yes/no Screening for TB - yes/no Isoniazid preventive therapy – yes/no

Strategies for prevention of TB in persons with HIV infection The “three I’s” (from WHO) 1.Intensified TB case finding 2. Isoniazid preventive therapy 3. Infection control in health care facilities Anti-retroviral therapy

Tuberculosis pathogenesis

Natural history of TB Exposure to an infectious case Focus in infection in lung Silent dissemination of infection and containment by host defenses (98%) Latent TB infection Pt asymptomatic, TST positive Activation of latent infection (5-10%) Patient symptomatic, based on site of activation (70% pulmonary) Lifetime dormancy (90-95%)

Preventive Interventions against TB Exposure to an infectious case Focus in infection in lung Dissemination of infection and/or containment by host defenses Latent TB infection Activation of infection Patient symptomatic, based on site of activation (70% pulmonary) immunization Treatment of Latent TB Infection Treatment of active TB

Natural history of TB in persons with HIV infection Exposure to an infectious case Focus in infection in lung Silent dissemination of infection and containment by host defenses (98%) Latent TB infection Pt asymptomatic, TST pos/neg Activation of latent infection (Lifetime odds of disease 5-10%) Patient symptomatic, based on site of activation (70% pulmonary) Lifetime dormancy (??) Clinical dissemination And disease (1-2%) 25% Annual risk of disease 10% 75%

Preventive Interventions against TB in Persons with HIV infection Exposure to an infectious case Focus in infection in lung Dissemination of infection and/or containment by host defenses Latent TB infection Activation of infection Patient symptomatic, based on site of activation Immunization Treatment of Latent TB Infection Treatment of active TB ART Infection control ART

Summary of the effect of antiretroviral therapy on rates of active TB In multiple studies done in a variety of settings, use of antiretroviral therapy decreases the rate of active TB in the population being treated The effect of antiretroviral therapy is greatest in areas with high rates of TB and among patients with lower CD4 cell counts Decreasing the risk of active TB is an important benefit of antiretroviral therapy

Traditional DOTS approach to TB case detection A patient seeks medical care, generally in aprimary health center, because of feelingunwell The patient is identified as a TB suspect on thebasis of typical symptoms: cough >2 weeks induration, fever, loss of weight The diagnosis of TB is made most often bymicroscopic examination of sputum for acid-fast bacilli

TB treatment

The advantages of early detection of TB cases in persons with HIV infection Early case detection leads to early institution of treatment, and to  A better chance for cure for the sick patient, and  Early termination of infectiousness and transmission Early case detection allows early assessment of contacts, including children, for TB and HIV infection

The importance of early detection of TB in persons with HIV infection A study from South Africa* found that patients with HIV infection who were found to have active TB on routine screening were six times less likely to die during TB treatment that those who sought care for TB associated symptoms *Churchyard et al. Int J Tuberc Lung Dis 4: , 2000

Proposed flow chart for IPT in patients with HIV infection Ait-Khaled et al. Int J Tuberc Lung Dis 13:927, 2009 TST?

TB Rates by ART and INH Treatment Status, Exposure category Person- Years TB Cases Incidence Rate (per 100 PYs) Incidence Rate Ratio No Rx3, ( )1.0 ART only11, ( )0.48 ( ) IPT only ( )0.32 ( ) Both1, ( )0.20 ( ) Total17, ( ) Golub et al., AIDS 2007;21:1441-8

Efficacy of IPT in reducing the risk of TB in HIV+ Adults 11 randomised trials with 8,130 HIV+ participants  overall reduction in TB = 36%, reduction PPD+ = 62% Woldehanna and Volmink, Cochrane Review 2006

Despite good evidence of IPT efficacy, recommendations from WHO guidelines, and the adoption of national guidelines, in 2007 only 0.1% (29,000) of the estimated 33.2 million people living with HIV infection were put on IPT. Why is this?

Unresolved issues with IPT Who should supervise IPT? Should tuberculin skin testing be used to identify IPT candidates? How and in whom should active TB be ruled out? Does IPT lead to an increased risk of INH resistance? How durable is a 6-9 month course of IPT? How safe is IPT in patients receiving ART?

Side effects of INH GI intolerancePIs, ZDV, ddI Skin rashABC, NNRTIs, Peripheral neuropathy ddI, d4T, ddC (Rare if pyridoxine is given concomitantly) Hepatotoxicity PIs, NNRTIs Effect also seen with ARVs

Types of adverse events from INH for latent TB in persons with HIV infection - Zambia Adverse event leading to drug discontinuation Hepatitis Rash GI symptoms Others Placebo (n = 360) 0 1 (0.3%) 2 (0.6%) INH (n = 360) 3 (0.8%) 1 (0.3%) 5 (1.4%) 3 (0.8%) AIDS 1998;12:

effect of IPT on drug susceptibility of subsequent TB cases – South African gold miners TB Cases following IPT (n = 57) TB cases in comparison group (n = 97) INH resistant cases 7 (13.2%) 8(8.2%) Churchyard G, et al. Unpublished observations

Topic for discussion How does your institution protect its staff members, including those with HIV infection, from acquiring TB?

The importance of TB infection control in HIV care Because undiagnosed TB is so common in PLWHA, TB is being transmitted in health care facilities from patient to patient and to health care workers Health care workers are 5-fold more likely to acquire TB compared to the general population Outpatient and inpatient sites are potential sites of TB spread: Emergency rooms, hospital wards, primary health care clinics, ART clinics, PMTCT clinics, VCT sites, and other sites inclujding jails, drug rehab centers…. Approximately half of cases in the XDR-TB outbreak in Kwa-Zulu Natal, South Africa were associated with health care sites

To reduce the spread of TB, all HIV care facilities should implement… Good work practices and administrative control measures Environmental control measures WHO 2009

The hallmark of good work practices to control TB is a TB infection control plan Through screening, identify TB suspects and and separate them from other patients in a well ventilated space Institute cough hygiene for TB suspects, including tissues and face masks Minimize time TB suspects spend in clinic, but deliver services they came for Evaluate TB suspects promptly or have a plan to refer them for evaluation Identify an Infection Control Officer to administer the plan

Environmental control measures for prevention of TB spread Environmental control is secondary to good work practices Mechanical ventilation systems are expensive and suitable for referral hospitals Natural ventilation can be utilized in many health care settings Open windows, open doors, and fans can efficiently bring outside air into a room, diluting droplet nuclei containing M.tb.

Thank you! Listserv: Next session: December 3 – HIV and Women

Thank you! Next session: December 3, 2009 Dr Scott McClelland HIV and Women, Part 2